future 10 2 103 1985 as stated above the combination of r x y substituted phenylacetic acid and r x y substituted phenylacetylglutamine of the present invention is useful in the treatment of autoimmune diseases pharmaceutical compositions including these active compounds can be prepared as described below mixtures of the active compounds or pharmaceutically acceptable salts thereof are included in the pharmaceutically acceptable carrier or diluent in an amount sufficient to exert a therapeutic effect without serious side effect the combination of active materials can be administered by any appropriate route for example orally parenterally intravenously intradermally subcutaneously intraperitoneally or topically in liquid or solid form the concentration of active compounds in the drug composition will depend upon absorption inactivation and excretion rates of the active compound as well as other factors known to those skilled in the art it is to be noted that dosage values will also vary with the severity of the condition to be alleviated it is to be further understood that for any particular subject specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions the combination active ingredient may be administered at once or may.